MedPath

Monalizumab

Generic Name
Monalizumab
Drug Type
Biotech
CAS Number
1228763-95-8
Unique Ingredient Identifier
3ZXZ2V0588
Background

Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.

Clinical Trials
Related News

Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA

Phase 1
Withdrawn
Conditions
Adenocarcinoma of the Esophagus
Adenocarcinoma of the Gastroesophageal Junction
Squamous Cell Carcinoma of the Esophagus
Interventions
Other: Metabolic
Procedure: Surgery
First Posted Date
2017-10-12
Last Posted Date
2017-12-19
Lead Sponsor
Jules Bordet Institute
Registration Number
NCT03307941
Locations
🇧🇪

Institut Jules Bordet, Brussels, Belgium

Biomarker-based Study in R/M SCCHN

Phase 2
Active, not recruiting
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
Drug: standard of care
First Posted Date
2017-03-23
Last Posted Date
2023-11-03
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
340
Registration Number
NCT03088059
Locations
🇧🇪

CHU Saint-Pierre-Site Porte de Hal, Brussels, Belgium

🇮🇹

IRCCS - Fondazione G. Pascale, Napoli, Italy

🇬🇧

Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, United Kingdom

and more 30 locations

Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation

Phase 1
Conditions
Hematologic Malignancies
Interventions
First Posted Date
2016-10-03
Last Posted Date
2018-09-19
Lead Sponsor
Institut Paoli-Calmettes
Target Recruit Count
18
Registration Number
NCT02921685
Locations
🇫🇷

Institut Paoli Calmettes, Marseille, Bouches Du Rhônes, France

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Phase 1
Active, not recruiting
Conditions
Advanced Solid Tumors
Interventions
Drug: mFOLFOX6
First Posted Date
2016-02-02
Last Posted Date
2025-04-22
Lead Sponsor
MedImmune LLC
Target Recruit Count
383
Registration Number
NCT02671435
Locations
🇬🇧

Research Site, Sutton, United Kingdom

Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL

Phase 1
Terminated
Conditions
Chronic Lymphocytic Leukemia
Interventions
First Posted Date
2015-09-23
Last Posted Date
2019-12-17
Lead Sponsor
Innate Pharma
Target Recruit Count
22
Registration Number
NCT02557516
Locations
🇺🇸

The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies

Phase 1
Completed
Conditions
Gynecologic Cancer
Interventions
First Posted Date
2015-06-02
Last Posted Date
2023-08-04
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
59
Registration Number
NCT02459301
Locations
🇨🇦

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

🇨🇦

BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada

🇨🇦

London Regional Cancer Program, London, Ontario, Canada

and more 4 locations

Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity

Phase 1
Terminated
Conditions
Squamous Cell Carcinoma of the Oral Cavity
Interventions
Procedure: Standard Surgery
Radiation: Postsurgical Adjuvant Therapy
First Posted Date
2015-01-06
Last Posted Date
2017-01-04
Lead Sponsor
Innate Pharma
Target Recruit Count
3
Registration Number
NCT02331875
Locations
🇪🇸

Instituto Catalan de Oncologia - L'Hospitalet, L'Hospitalet de Llobregat Barcelona, Spain

🇪🇸

Hospital Universitario La Paz, Madrid, Spain

🇩🇪

Charité University Medicine Berlin, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy